These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1187 related items for PubMed ID: 25378643

  • 1. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
    Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.
    Sci Transl Med; 2014 Nov 05; 6(261):261ra151. PubMed ID: 25378643
    [Abstract] [Full Text] [Related]

  • 2. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, Spicer JF, King J, Maher J.
    Cancer Lett; 2017 May 01; 393():52-59. PubMed ID: 28223167
    [Abstract] [Full Text] [Related]

  • 3. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
    Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH.
    Cancer Immunol Res; 2014 Feb 01; 2(2):112-20. PubMed ID: 24579088
    [Abstract] [Full Text] [Related]

  • 4. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
    Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM.
    Clin Cancer Res; 2014 Aug 15; 20(16):4262-73. PubMed ID: 24919573
    [Abstract] [Full Text] [Related]

  • 5. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
    Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ, Riley JL, June CH, Albelda SM.
    Clin Cancer Res; 2011 Jul 15; 17(14):4719-30. PubMed ID: 21610146
    [Abstract] [Full Text] [Related]

  • 6. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
    Gulati P, Rühl J, Kannan A, Pircher M, Schuberth P, Nytko KJ, Pruschy M, Sulser S, Haefner M, Jensen S, Soltermann A, Jungraithmayr W, Eisenring M, Winder T, Samaras P, Tabor A, Stenger R, Stupp R, Weder W, Renner C, Münz C, Petrausch U.
    Clin Cancer Res; 2018 Aug 15; 24(16):3981-3993. PubMed ID: 29748183
    [Abstract] [Full Text] [Related]

  • 7. Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model.
    Wang Y, Wang J, Yang X, Yang J, Lu P, Zhao L, Li B, Pan H, Jiang Z, Shen X, Liang Z, Liang Y, Zhu H.
    Front Immunol; 2021 Aug 15; 12():628906. PubMed ID: 33777013
    [Abstract] [Full Text] [Related]

  • 8. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
    Yu Z, Tan Z, Lee BK, Tang J, Wu X, Cheung KW, Lo NT, Man K, Liu L, Chen Z.
    Oncotarget; 2015 Oct 20; 6(32):32426-38. PubMed ID: 26431275
    [Abstract] [Full Text] [Related]

  • 9. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.
    Mayor M, Zeltsman M, McGee E, Adusumilli PS.
    Immunotherapy; 2016 May 20; 8(5):491-4. PubMed ID: 27140404
    [No Abstract] [Full Text] [Related]

  • 10. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
    Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH.
    Cancer Immunol Res; 2013 Jul 20; 1(1):26-31. PubMed ID: 24777247
    [Abstract] [Full Text] [Related]

  • 11. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
    Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, Soltermann A, Jüngel A, Marroquin Belaunzaran O, Stahel R, Renner C, Petrausch U.
    J Transl Med; 2013 Aug 12; 11():187. PubMed ID: 23937772
    [Abstract] [Full Text] [Related]

  • 12. Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy.
    Quach HT, Skovgard MS, Villena-Vargas J, Bellis RY, Chintala NK, Amador-Molina A, Bai Y, Banerjee S, Saini J, Xiong Y, Vista WR, Byun AJ, De Biasi A, Zeltsman M, Mayor M, Morello A, Mittal V, Gomez DR, Rimner A, Jones DR, Adusumilli PS.
    Cancer Immunol Res; 2023 Oct 04; 11(10):1314-1331. PubMed ID: 37540803
    [Abstract] [Full Text] [Related]

  • 13. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
    O'Hara MH, Stashwick C, Plesa G, Tanyi JL.
    Immunotherapy; 2017 Aug 04; 9(9):767-780. PubMed ID: 28771103
    [Abstract] [Full Text] [Related]

  • 14. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
    Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH.
    Cancer Res; 2010 Nov 15; 70(22):9053-61. PubMed ID: 20926399
    [Abstract] [Full Text] [Related]

  • 15. Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
    de Goeje PL, Klaver Y, Kaijen-Lambers MEH, Langerak AW, Vroman H, Kunert A, Lamers CHJ, Aerts JGJV, Debets R, Hendriks RW.
    Front Immunol; 2018 Nov 15; 9():2034. PubMed ID: 30245692
    [Abstract] [Full Text] [Related]

  • 16. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.
    Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, Coussens LM, Brockstedt DG.
    Clin Cancer Res; 2019 Oct 01; 25(19):5787-5798. PubMed ID: 31263030
    [Abstract] [Full Text] [Related]

  • 17. Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.
    Tomar S, Zhang J, Khanal M, Hong J, Venugopalan A, Jiang Q, Sengupta M, Miettinen M, Li N, Pastan I, Ho M, Hassan R.
    Mol Cancer Ther; 2022 Jul 05; 21(7):1195-1206. PubMed ID: 35499461
    [Abstract] [Full Text] [Related]

  • 18. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y.
    Cancer Sci; 2016 Sep 05; 107(9):1198-205. PubMed ID: 27294401
    [Abstract] [Full Text] [Related]

  • 19. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
    Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, Powell DJ.
    Cancer Immunol Res; 2013 Jul 05; 1(1):43-53. PubMed ID: 24409448
    [Abstract] [Full Text] [Related]

  • 20. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
    Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV, Emens LA.
    Hum Gene Ther; 2018 May 05; 29(5):614-625. PubMed ID: 29334771
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.